Takeda Pharmaceutical on Wednesday said it will acquire GammaDelta Therapeutics, a London-based biotech company specializing in off-the-shelf cell therapy for cancer and the Japanese drugmaker's research partner since 2017.
LONDON--(BUSINESS WIRE)--GammaDelta Therapeutics Ltd. (GDT), a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer, today announced that it has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukaemia (AML). GDX012 is an allogeneic, non-engineered, variable delta 1 (V?1) gamma-delta (??) T cell therapy manufactured from healthy donor blood.